Trial Profile

A Phase I, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of QL1604, a Humanized Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iparomlimab (Primary)
Indications Carcinoma; Malignant thymoma; Nasopharyngeal cancer; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Qilu Pharmaceutical

06 Nov 2023 Status changed from active, no longer recruiting to completed, according to Qilu pharmaceutical media release.
06 Nov 2023 According to Qilu pharmaceutical media release, result of this study were published online in the academic journal Frontiers in Immunology.
06 Nov 2023 Results presented in a Qilu Pharmaceutical media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com